Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place from September 4-6, 2024, at the Marriott Marquis in New York City.
Key executives, including CEO Ben Zeskind and CSO Brett Hall, will present in a fireside chat format on September 6 from 10:00 – 10:35 am ET. They will discuss Immuneering's pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for broad populations of cancer patients.
The presentation will be webcast live and archived on Immuneering's website in the Investor Relations section. This event provides an opportunity for investors to gain insights into the company's progress and future plans in the oncology field.
Immuneering (Nasdaq: IMRX), una compagnia oncologica in fase clinica, ha annunciato la sua partecipazione alla 22ª Conferenza Sanitaria Globale Annuale di Morgan Stanley. L'evento si svolgerà dal 4 al 6 settembre 2024 presso il Marriott Marquis a New York City.
Alcuni dirigenti chiave, tra cui il CEO Ben Zeskind e il CSO Brett Hall, parteciperanno a una conversazione informale il 6 settembre dalle 10:00 alle 10:35 ET. Discuteranno del pipeline, della piattaforma e della strategia commerciale di Immuneering, concentrandosi sullo sviluppo di medicinali universali RAS/RAF per ampie popolazioni di pazienti oncologici.
La presentazione sarà trasmessa in diretta e registrata sul sito web di Immuneering nella sezione Relazioni con gli Investitori. Questo evento offre un'opportunità agli investitori per ottenere informazioni sui progressi dell'azienda e sui futuri piani nel campo oncologico.
Immuneering (Nasdaq: IMRX), una empresa de oncología en etapa clínica, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El evento se llevará a cabo del 4 al 6 de septiembre de 2024 en el Marriott Marquis en la ciudad de Nueva York.
Ejecutivos clave, incluido el CEO Ben Zeskind y el CSO Brett Hall, participarán en un formato de charla informal el 6 de septiembre de 10:00 a 10:35 am ET. Discutirán sobre la cartera de productos, la plataforma y la estrategia comercial de Immuneering, centrándose en el desarrollo de medicamentos universales RAS/RAF para amplias poblaciones de pacientes con cáncer.
La presentación se transmitirá en vivo y se archivará en el sitio web de Immuneering en la sección de Relaciones con Inversores. Este evento proporciona una oportunidad para que los inversores obtengan información sobre el progreso y los planes futuros de la empresa en el campo de la oncología.
Immuneering (Nasdaq: IMRX), 임상 단계의 종양학 회사가 모건 스탠리 제22회 연례 글로벌 건강 관리 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 9월 4일부터 6일까지 뉴욕시의 메리어트 마르키스에서 열릴 예정입니다.
CEO 벤 제스킨드와 CSO 브렛 홀을 포함한 주요 임원들이 9월 6일 오전 10시부터 10시 35분 ET까지 비공식 대담 형식으로 발표할 것입니다. 그들은 Immuneering의 파이프라인, 플랫폼 및 비즈니스 전략에 대해 논의하며, 암 환자들의 광범위한 인구를 위한 범용 RAS/RAF 의약품 개발에 초점을 맞출 것입니다.
발표는 실시간 웹캐스트 및 기록 보관 될 예정이며, Immuneering의 투자자 관계 섹션 웹사이트에서 확인할 수 있습니다. 이 행사는 투자자들이 회사의 진행 상황과 향후 계획에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Immuneering (Nasdaq: IMRX), une entreprise d'oncologie en phase clinique, a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. L'événement se déroulera du 4 au 6 septembre 2024 au Marriott Marquis à New York.
Des dirigeants clés, dont le PDG Ben Zeskind et le CSO Brett Hall, participeront à une discussion informelle le 6 septembre de 10h00 à 10h35 ET. Ils discuteront du pipeline, de la plateforme et de la stratégie commerciale d'Immuneering, en se concentrant sur le développement de médicaments universels RAS/RAF pour de larges populations de patients atteints de cancer.
La présentation sera transmise en direct et archivée sur le site Web d'Immuneering dans la section Relations Investisseurs. Cet événement offre une occasion aux investisseurs d'obtenir des informations sur les progrès de l'entreprise et ses projets futurs dans le domaine oncologique.
Immuneering (Nasdaq: IMRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Die Veranstaltung findet vom 4. bis 6. September 2024 im Marriott Marquis in New York City statt.
Wichtige Führungskräfte, darunter CEO Ben Zeskind und CSO Brett Hall, werden am 6. September von 10:00 bis 10:35 Uhr ET in einem informellen Gesprächsformat präsentieren. Sie werden über Immuneerings Pipeline, Plattform und Geschäftsstrategie sprechen und sich auf die Entwicklung universeller RAS/RAF-Medikamente für breite Bevölkerungsgruppen von Krebspatienten konzentrieren.
Die Präsentation wird live übertragen und aufgezeichnet auf der Website von Immuneering im Bereich Investor Relations. Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in die Fortschritte und zukünftigen Pläne des Unternehmens im Bereich der Onkologie zu erhalten.
- None.
- None.
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from September 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer and Secretary and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: September 6 from 10:00 – 10:35 am ET
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering (IMRX) presenting at the Morgan Stanley Healthcare Conference?
Where can I watch Immuneering's (IMRX) presentation at the Morgan Stanley conference?
What will Immuneering (IMRX) discuss at the Morgan Stanley Healthcare Conference?
Which Immuneering (IMRX) executives are participating in the Morgan Stanley conference?
